Skip to content
Screener

Incyte INCY Common Stock Shares Issued

Common Stock Shares Issued at other companies

Gilead Sciences logo
Gilead SciencesGILD
1.2B-0.1%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
75.8M+2.1%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
125.6M+4.8%
Arcus Biosciences logo
Arcus BiosciencesRCUS
127M+19.4%
Exelixis logo
ExelixisEXEL
248.9M-7.9%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
1B+22.7%

Other financials

Income statement

See full
Revenue$1.7B+37.7%
Gross profit$1.6B+38.0%
Operating income$697.9M+31.6%
Net income$585.6M+44.6%
EPS (diluted)$2.81+37.7%

Balance sheet

See full
Cash & equivalents$4.0B+104%
Total debt$38.3M-9.8%
Total equity$6.3B+52.1%
Total assets$7.9B+35.2%

Cash flow

See full
Operating cash flow$507.7M+1,035%
CapEx$1.6M-43.5%
Free cash flow$509.3M+1,069%

Valuation

See full
Market cap$24.64B+59.3%
Enterprise value$20.69B+52.7%
P/E15.3×-2.5×
P/S4.2×+0.9×

Profitability

See full
Gross margin92.6%-0.3pp
Operating margin30.6%+4.8pp
Net margin27.7%+8.7pp
FCF margin34%+12.3pp

Returns & leverage

See full
Return on equity30.7%+6.4pp
Debt / equity0.0×
Current ratio4.6×+1.7×

Where this comes from

Reported directly by Incyte in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesIssued.

The source filing: Incyte’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:02 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000879169-26-000056
Line itemJune 30,2026December 31,2025*
Commitments and contingencies (Note 15)
Stockholders’ equity:
Preferred Stock, $0.001 par value; 5,000,000 shares authorized; none issued or outstanding
Common Stock, $0.001 par value; 400,000,000 shares authorized; 200,977,687 and 198,460,009 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively201198
Additional paid-in capital5,221,8044,928,049
Accumulated other comprehensive income19,71825,462
Retained earnings1,102,704213,769
Total stockholders’ equity6,344,4275,167,478

Item 1. Financial Statements

FAQ

What is Incyte's common stock shares issued?
Incyte (INCY) reported common stock shares issued of 201M in Q2 2026.
How has Incyte's common stock shares issued changed year-over-year?
Incyte's common stock shares issued increased by 3.5% year-over-year, from 194.1M to 201M.
What is the long-term trend for Incyte's common stock shares issued?
Over 4 years (2021 to 2025), Incyte's common stock shares issued has grown at a -2.7% compound annual growth rate (CAGR), from 221.1M to 198.5M.
What does common stock shares issued mean?
The total number of shares that have been authorized and distributed by the corporation since its inception. This includes shares held by the public (outstanding) as well as any shares that the company has repurchased and holds in its treasury. It represents the historical volume of equity capital creation.

Ask your AI about Incyte's common stock shares issued.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude